CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 38 enrolled
Drug / intervention
Pembrolizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02007070
NCT02007070Phase 1Completed
CompareCT.gov

An Open-label, Non-randomized, Multi-center Phase Ib Study of MK-3475 in Subjects With PD-L1 Positive Advanced Non-small Cell Lung Cancer

Merck Sharp & Dohme LLC·interventional·Posted Dec 10, 2013·Updated May 13, 2020

In Brief

A Phase 1 clinical trial evaluating Pembrolizumab for Non-small Cell Lung Cancer. Completed, enrolled 38 participants.

Detailed Summary

This study is being done to evaluate the safety and efficacy of pembrolizumab (MK-3475) in participants with advanced non-small cell lung cancer (NSCLC) tumors that are positive for programmed cell death ligand 1 (PD-L1): the hypothesis is that treatment with pembrolizumab will result in a clinically meaningful Overall Response Rate (ORR).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 10, 2013
Enrollment StartFeb 28, 2014
Primary CompletionJul 9, 2015
Study CompletionMar 31, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.6 years ago

Interventions

Pembrolizumabbiological

Intravenous infusion